Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenetics--expectations and reality.

Literature DB >> 15231589

Pharmacogenetics--expectations and reality.

Geoff Tucker.

Abstract

Mesh：

Substances：

Year: 2004 PMID： 15231589 PMCID： PMC443427 DOI： 10.1136/bmj.329.7456.4

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

7 in total

1. Assessing the cost-effectiveness of pharmacogenomics.

Authors: D L Veenstra; M K Higashi; K A Phillips
Journal: AAPS PharmSci Date: 2000

2. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response.

Authors: John Urquhart
Journal: Br J Clin Pharmacol Date: 2002-08 Impact factor: 4.335

3. The potential and limitations of personalised medicine in primary care.

Authors: Rhydian Hapgood
Journal: Br J Gen Pract Date: 2003-12 Impact factor: 5.386

4. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544

5. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors: Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal: Lancet Date: 2002-03-30 Impact factor: 79.321

Review 6. Race, distributive justice and the promise of pharmacogenomics: ethical considerations.

Authors: Sandra Soo-Jin Lee
Journal: Am J Pharmacogenomics Date: 2003

7. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Authors: Brian F Gage; Charles Eby; Paul E Milligan; Gerald A Banet; Jill R Duncan; Howard L McLeod
Journal: Thromb Haemost Date: 2004-01 Impact factor: 5.249

7 in total

12 in total

Pharmacogenetics--expectations and reality.

1. Assessing the cost-effectiveness of pharmacogenomics.

2. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response.

3. The potential and limitations of personalised medicine in primary care.

4. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

5. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Review 6. Race, distributive justice and the promise of pharmacogenomics: ethical considerations.

7. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Review 1. Making decisions about benefits and harms of medicines.

2. Drug development: more science, more education.

Review 3. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?

Review 4. Pharmacogenetics in drug regulation: promise, potential and pitfalls.

5. Genetic epidemiology and primary care.

6. Genetic polymorphisms, drug metabolism and drug concentrations.

7. Acetylation pharmacogenetics and renal function in diabetes mellitus patients.

8. Linking pharmacovigilance with pharmacogenetics.

Review 9. Chronic heart failure: beta-blockers and pharmacogenetics.

10. Role of Statistical Random-Effects Linear Models in Personalized Medicine.